At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 26 enrolled
Drug / intervention
Snake (Micrurus) North American immune F(ab')2 Equinedrug
Likely dose
Snake (Micrurus) North American immune F(ab')2 Equine 250 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Emergency Treatment of Coral Snake Envenomation With Antivenom
In Brief
A Phase 3 clinical trial evaluating Snake (Micrurus) North American immune F(ab')2 Equine for Coral Snake Bite and Toxic Effect of Coral Snake Venom. Completed, enrolled 26 participants across 5 sites.
Detailed Summary
The purpose of this study is to see whether a new F(ab')2 antivenom will prevent injury and death from the bite of a coral snake. Funding Source - FDA OOPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2011
Enrollment StartMay 2012
Primary CompletionNov 2016
TodayJul 2026
First PostedApr 18, 2011
Enrollment StartMay 1, 2012
Primary CompletionNov 11, 2016
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 15.2 years ago
Interventions
Snake (Micrurus) North American immune F(ab')2 Equinedrug
5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.